Meeting
2019 Gastrointestinal Cancers Symposium
Neoadjuvant multimodal treatment of borderline resectable (BRPC) and locally advanced unresectable pancreatic cancer (LAPC) in Mexico.
Authors
Vanessa Rosas Camargo
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, DF, Mexico
Vanessa Rosas Camargo , Edgar Omar Martos Armedáriz , Miriam Heidi Cisneros Cordero , ZULEYMA NIETO GARCIA , Christian Haydeé Flores Balcázar , Mónica Isabel Meneses Medina , Carlos Chan Nuñez , Armando Gamboa Dominguez , Fidel David Huitzil Melendez
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 454)
DOI
10.1200/JCO.2019.37.4_suppl.454
Abstract #
454
Poster Bd #
P14
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Role of neoadjuvant treatment regimens for locally advanced pancreatic cancer.
First Author: Mohammad Alfayez
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka
Poster
2021 ASCO Annual Meeting
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
First Author: Nai-Jung Chiang